Search by keyword

21 result(s) found, displaying 1 to 20 | Clear filters

2020
Guide, user guide or guidelines

The Commission has revised the National Tall Man Lettering List to include cloBAZam in the benzodiazepine class of medicines, based on the reporting of adverse events and near misses and its high similarity and likelihood of confusion with another benzodiazepine: CLONAZepam.

2020
Guide, user guide or guidelines

This User Guide describes best practice strategies under each of the 28 specific actions to support organisations to deliver effective medication management in cancer services.

2020
Guide, user guide or guidelines

The purpose of this guide is to provide clinicians with evidence-based strategies to support them to understand and fulfil their roles and responsibilities. It combines information from a range of existing guides and resources, including the National Safety and Quality Health Service Standards User Guide for Medication Management in Cancer Care.

2020
Guide, user guide or guidelines

Last updated 27 August 2020

2020
Guide, user guide or guidelines

Last updated 28 April 2020

2020
Guide, user guide or guidelines

Last updated 29 April 2020

2020
Guide, user guide or guidelines

Last updated 15 May 2020

2020
Guide, user guide or guidelines

Last updated 28 April 2020

2020
Guide, user guide or guidelines

Last updated 28 April 2020

2020
Guide, user guide or guidelines

Last updated 29 April 2020

2020
Guide, user guide or guidelines

Last updated 28 April 2020

2020
Guide, user guide or guidelines

Last updated 12 May 2020

2020
Guide, user guide or guidelines

This guidance outlines strategies and principles developed to address safe selection and storage of all medicines, including look-alike, sound-alike (LASA) medicines.

2020
Guide, user guide or guidelines

This survey tool provides Australian health service organisations with a set of 14 principles supported by a variety of risk reduction strategies. The tool should be used in conjunction with the Principles for the safe selection and storage of medicines – Guidance and survey tool.

2020
Guide, user guide or guidelines

Last updated 21 August 2020

2020
Guide, user guide or guidelines

Date of revision: 25 August 2020

2020
Guide, user guide or guidelines

This user guide supports prescribers to prescribe medicines by the active ingredient with best practice guidance for specification of brand.

2020
Guide, user guide or guidelines

The Active ingredient prescribing – User guide for Australian prescribers supports prescribers to prescribe medicines by the active ingredient with best practice guidance for specification of brand. Principles are outlined in the user guide to determine when prescribers should consider brand name specification if clinically necessary. Specifying the brand name may be necessary to support safe and quality use of a medicine where consumer harm could result from switching between medicine brands or to ensure prescriber instructions are suitable for the dispensed medicine.

This List of Medicines for Brand Consideration includes medicines prescribers should consider prescribing by brand as well as active ingredient, if clinically necessary for the treatment of their patient. For example, in situations where formulations are not interchangeable due to variations in delivery of the active ingredient, prescribers should consider specification by brand for patient safety.